Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
arcticnovartis
Fri, 04/24/2026 – 07:19
Read more about Novartis malaria treatment Coartem® Baby receives WHO prequ…
Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
arcticnovartis
Fri, 04/24/2026 – 07:19
Read more about Novartis malaria treatment Coartem® Baby receives WHO prequ…
Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
arcticnovartis
Fri, 04/24/2026 – 07:17
Read more about Novartis malaria treatment Coartem® Baby receives WHO prequ…
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
arcticnovartis
Thu, 04/09/2026 – 07:19
Read more about Novartis announces expansion of community hea…
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
arcticnovartis
Sun, 03/29/2026 – 07:19
Read more about Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney …
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
arcticnovartis
Fri, 03/27/2026 – 07:02
Read more about Novartis agrees to acquire Excellergy, Inc., building on allergy leadership…
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
arcticnovartis
Fri, 03/27/2026 – 07:02
Read more about Novartis agrees to acquire Excellergy, Inc., building on allergy leadership…
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
arcticnovartis
Fri, 03/27/2026 – 07:02
Read more about Novartis agrees to acquire Excellergy, Inc., building on allergy leadership…
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
arcticnovartis
Mon, 03/23/2026 – 07:19
Read more about Novartis presents new data on early symptom relief and long-term control in comple…
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
arcticnovartis
Fri, 03/20/2026 – 07:04
Read more about Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its…
